The Dupont Merck Pharmaceutical Company

Dupont Pharmaceuticals Company

William Frank Degrado

Shaker Ahmed Mousa

John Wityak

Chu-Biao Xue

Richard Eric Olson

Shuang Liu

Douglas G Batt

Milind Rajopadhye

Thomas David Harris

Gary Avonn Cain

Donald J Pinto

Michael Sworin

Munir A Hussain

Gregory J Wells

Anju Parthasarathy

Sharon Anne Jackson

Thais Motria Sielecki-Dzurdz

Scott David Edwards

John Andrew Barrett

Philip Ma

Lin-Hua Zhang

This invention relates to novel isoxazolines and isoxazoles which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex or the vitronectin receptor, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.

Isoxazoline and isoxazole fibrogen receptor antagonists

This invention provides novel radiopharmaceuticals that are radiolabeled cyclic compounds containing carbocyclic or heterocyclic ring systems which act as antagonists of the platelet glycoprotein IIb/IIIa complex; to methods of using said radiopharmaceuticals as imaging agents for the diagnosis of arterial and venous thrombi; to novel reagents for the preparation of said radiopharmaceuticals; and to kits comprising said reagents.

Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents

This invention relates to novel cyclic compounds linked by a heterocyclic ring system, which are useful as antagonists of the platelet glycoprotein IIb/IIIa complex, to pharmaceutical compositions containing such cyclic compounds, and to methods of using these compounds for the inhibition of platelet aggregation.

Cyclic compounds linked by a heterocyclic ring useful as inhibitors of

Isoxazoline and isoxazole fibrinogen receptor antagonists

This invention provides processes for the synthesis of platelet glycoprotein IIb/IIIa inhibitors and intermediate compounds useful in said processes. The compounds afforded by this invention have the formula: ##STR1##

Processes and intermediate compounds for the preparation of platelet

This invention relates to novel cyclic compounds linked by a heterocyclic ring system, which are useful as antagonists of the platelet glycoprotein IIb/IIIa complex, to pharmaceutical compositions containing such cyclic compounds, and to methods of using these compounds for the inhibition of platelet aggregation. A representative compound of the invention is cyclo-(D-Val-N(Me)Arg-Gly-Asp-�5-aminomethyl!-2-furoate).

This invention relates to novel compounds containing basic and acidic termini, pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.

Compounds containing basic and acidic termini useful as fibrinogen

Growing community of inventors

Moylan, PA, United States of America

William Frank Degrado